Patterns and determinants of new first-line antihyperglycaemic drug use in patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 106, Issue 1, 2014, Pages 73-80

  Geier, A S ^a   Wellmann, I ^a   Wellmann, J ^a   Kajuter H ^b   Heidinger, O ^b   Hempel, G ^a   Hense, H W ^a,b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Epidemiological Cancer Registry for the State of North Rhine Westphalia   (Germany)

Author keywords

Disease management program; Health services research; Pharmacotherapy; Prescription patterns; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE RECEPTOR AGONIST; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DRUG CHOICE; DRUG UTILIZATION; FEMALE; GERMANY; HEALTH INSURANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRESCRIPTION; TREATMENT DURATION; TREND STUDY; CLINICAL PRACTICE; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; TIME;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; SULFONYLUREA COMPOUNDS; TIME FACTORS;

EID: 84908031405     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.07.014     Document Type: Article

References (37)

1. Guariguata L., Whiting D.R., Hambleton I., Beagley J., Linnenkamp U., Shaw J.E. Global estimates of diabetes prevalence in adults for 2013 and projections for 2035 for the IDF Diabetes Atlas. Diabetes Res Clin Pract 2014, 103(2):137-149.
2. Rathmann W., Scheidt-Nave C., Roden M., Herder C. Type 2 diabetes: prevalence and relevance of genetic and acquired factors for its prediction. Dtsch Arztebl Int 2013, 110(19):331-337.
3. Heidemann C., Du Y., Schubert I., Rathmann W., Scheidt-Nave C. Prevalence and temporal trend of known diabetes mellitus: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013, 56(5-6):668-677.
4. Stock S., Drabik A., Buscher G., Graf C., Ullrich W., Gerber A., et al. German diabetes management programs improve quality of care and curb costs. Health Aff (Millwood) 2010, 29(12):2197-2205.
5. Zwanzigste Verordnung zur Änderung der Risikostruktur-Ausgleichsverordnung, Bundesgesetzblatt Jahrgang 2009 Teil I Nr. 35. Available from (accessed 11.04.14). http://www.g-ba.de/downloads/62-492-353/2009-07-01-RSAV20.pdf.
6. Matthaei S., Bierwirth R., Fritsche A., Gallwitz B., Haring H.U., Joost H.G., et al. Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes 2009, 117(9):522-557.
7. Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Sherwin R., et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006, 49(8):1711-1721.
8. Kramer H.U., Ruter G., Schottker B., Rothenbacher D., Rosemann T., Szecsenyi J., et al. Gender differences in healthcare utilization of patients with diabetes. Am J Manag Care 2012, 18(7):362-369.
9. Lehnert H., Wittchen H.U., Pittrow D., Bramlage P., Kirch W., Bohler S., et al. Prevalence and pharmacotherapy of diabetes mellitus in primary care. Dtsch Med Wochenschr 2005, 130(7):323-328.
10. Pittrow D., Stalla G.K., Zeiher A.M., Silber S., Marz W., Pieper L., et al. Prevalence: drug treatment and metabolic control of diabetes mellitus in primary care. Med Klin (Munich) 2006, 101(8):635-644.
11. Pawaskar M., Zagar A., Sugihara T., Shi L. Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis. J Med Econ 2011, 14(1):16-27.
12. Desai N.R., Shrank W.H., Fischer M.A., Avorn J., Liberman J.N., Schneeweiss S., et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 2012, 125(3):302-307.
13. Mino-Leon D., Figueras A., Amato D., Laporte J.R. Treatment of type 2 diabetes in primary health care: a drug utilization study. Ann Pharmacother 2005, 39(3):441-445.
14. Thiebaud P., Demand M., Wolf S.A., Alipuria L.L., Ye Q., Gutierrez P.R. Impact of disease management on utilization and adherence with drugs and tests: the case of diabetes treatment in the Florida: a Healthy State (FAHS) program. Diabetes Care 2008, 31(9):1717-1722.
15. Foster P.D., Mamdani M.M., Juurlink D.N., Shah B.R., Paterson J.M., Gomes T. Trends in selection and timing of first-line pharmacotherapy in older patients with type 2 diabetes diagnosed between 1994 and 2006. Diabet Med 2013, 30(10):1209-1213.
16. Cohen F.J., Neslusan C.A., Conklin J.E., Song X. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care 2003, 26(6):1847-1851.
17. Boyc K.S., Yurgin N., Lage M.J. Trends in the prescription of antidiabetic medications in France: evidence from primary care physicians. Adv Ther 2007, 24(4):803-813.
18. Filion K.B., Joseph L., Boivin J.F., Suissa S., Brophy J.M. Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. Pharmacoepidemiol Drug Saf 2009, 18(10):973-976.
19. Brouwer E.S., West S.L., Kluckman M., Wallace D., Masica A.L., Ewen E., et al. Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record. Pharmacoepidemiol Drug Saf 2012, 21(9):920-928.
20. Abdelmoneim A.S., Eurich D.T., Gamble J.M., Simpson S.H. Use patterns of antidiabetic regimens by patients with type 2 diabetes. Can J Diabetes 2013, 37(6):394-400.
21. Kajuter H., Batzler W.U., Krieg V., Heidinger O., Hense H.W. Linkage of secondary data with cancer registry data on the basis of encrypted personal identifiers - results from a pilot study in North Rhine-Westphalia. Gesundheitswesen 2012.
22. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18(6):695-706.
23. Sinclair A.J., Alexander C.M., Davies M.J., Zhao C., Mavros P. Factors associated with initiation of antihyperglycaemic medication in UK patients with newly diagnosed type 2 diabetes. BMC Endocr Disord 2012, 12:1.
24. Spoelstra J.A., Stolk R.P., Klungel O.H., Erkens J.A., Rutten G.E., Leufkens H.G., et al. Initiation of glucose-lowering therapy in type 2 diabetes mellitus patients in general practice. Diabet Med 2004, 21(8):896-900.
25. Del P.S., Penno G., Miccoli R. Changing the treatment paradigm for type 2 diabetes. Diabetes Care 2009, 32(Suppl. 2):S217-S222.
26. Zhang Q., Marrett E., Jameson K., Meiler S., Davies M.J., Radican L., et al. Reasons given by general practitioners for non-treatment decisions in younger and older patients with newly diagnosed type 2 diabetes mellitus in the United Kingdom: a survey study. BMC Endocr Disord 2011, 11:17.
27. Hagen B., Kretschmann J., Weber A., Blaschy S., Groos S., Altenhofen L., et al. Gemeinsame Einrichtung Disease-Management-Programme Westfalen-Lippe (2012). Qualitätssicherungsbericht 2009 2012, Disease Management Programme in Westfalen-Lippe. (Hg.), Dortmund Gemeinsame Einrichtung DMP.
28. Arzneiverordnungs-Report 2012: Aktuelle Daten, Kosten, Trends und Kommentare 2012, Springer-Verlag, Berlin. Schwabe, Paffrath (Eds.).
29. Masoudi F.A., Inzucchi S.E., Wang Y., Havranek E.P., Foody J.M., Krumholz H.M. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005, 111(5):583-590.
30. Saenz A., Fernandez-Esteban I., Mataix A., Ausejo M., Roque M., Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005, 3:CD002966.
31. Cook M.N., Girman C.J., Stein P.P., Alexander C.M. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care. Diabet Med 2007, 24(4):350-358.
32. Zhang Q., Rajagopalan S., Marrett E., Davies M.J., Radican L., Engel S.S. Time to treatment initiation with oral antihyperglycaemic therapy in US patients with newly diagnosed type 2 diabetes. Diabetes Obes Metab 2012, 14(2):149-154.
33. Fu A.Z., Qiu Y., Davies M.J., Engel S.S. Initial sulfonylurea use and subsequent insulin therapy in older subjects with type 2 diabetes mellitus. Diabetes Ther 2012, 3(1):12.
34. Eurich D.T., Simpson S.H., Majumdar S.R., Johnson J.A. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus. Pharmacotherapy 2005, 25(6):810-816.
35. Nichols G.A., Alexander C.M., Girman C.J., Kamal-Bahl S.J., Brown J.B. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care 2006, 29(3):504-509.
36. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281(21):2005-2012.
37. Schafer I., Kuver C., Gedrose B., von Leitner E.C., Treszl A., Wegscheider K., et al. Selection effects may account for better outcomes of the German Disease Management Program for type 2 diabetes. BMC Health Serv Res 2010, 10:351.